Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)

PURPOSE: Limitations of the paclitaxel-doxorubicin-cisplatin (TAP) regimen in the treatment of endometrial cancer include tolerability and cumbersome scheduling. The Gynecologic Oncology Group studied carboplatin plus paclitaxel (TC) as a noninferior alternative to TAP. METHODS: GOG0209 was a phase...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Miller, David S., Filiaci, Virginia L., Mannel, Robert S., Cohn, David E., Matsumoto, Takashi, Tewari, Krishnansu S., DiSilvestro, Paul, Pearl, Michael L., Argenta, Peter A., Powell, Matthew A., Zweizig, Susan L., Warshal, David P., Hanjani, Parviz, Carney, Michael E., Huang, Helen, Cella, David, Zaino, Richard, Fleming, Gini F.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2020
Assuntos:
RAPID COMMUNICATIONS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7676887/
https://ncbi.nlm.nih.gov/pubmed/33078978
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.01076
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados